Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
1.980
-0.240 (-10.81%)
At close: Nov 21, 2024, 4:00 PM
2.000
+0.020 (1.01%)
After-hours: Nov 21, 2024, 5:42 PM EST
Mersana Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Cash & Equivalents | 78.87 | 174.56 | 128.89 | 177.95 | 255.09 | 62.35 | Upgrade
|
| Short-Term Investments | 76.3 | 34.52 | 151.83 | - | - | 37.44 | Upgrade
|
| Cash & Short-Term Investments | 155.17 | 209.08 | 280.71 | 177.95 | 255.09 | 99.79 | Upgrade
|
| Cash Growth | -35.61% | -25.52% | 57.75% | -30.24% | 155.63% | 42.29% | Upgrade
|
| Receivables | 1 | - | 30 | - | - | - | Upgrade
|
| Prepaid Expenses | 4.39 | 4.97 | 8.51 | 10.95 | 3.49 | 1.54 | Upgrade
|
| Total Current Assets | 160.56 | 214.06 | 319.22 | 188.9 | 258.58 | 101.33 | Upgrade
|
| Property, Plant & Equipment | 8 | 11.53 | 14.46 | 14.86 | 12.67 | 4.76 | Upgrade
|
| Other Long-Term Assets | 0.98 | 0.48 | 0.66 | 2.36 | 2.15 | 1.45 | Upgrade
|
| Total Assets | 169.53 | 226.06 | 334.34 | 206.11 | 273.4 | 107.54 | Upgrade
|
| Accounts Payable | 2.03 | 7.32 | 13.95 | 12.32 | 8.34 | 7.3 | Upgrade
|
| Accrued Expenses | 18.63 | 20.85 | 43.18 | 28.72 | 16.15 | 8.99 | Upgrade
|
| Current Portion of Long-Term Debt | 11.46 | 2.08 | - | - | - | 0.67 | Upgrade
|
| Current Portion of Leases | 3.75 | 3.4 | 3.04 | 2.54 | 1.53 | 2.31 | Upgrade
|
| Current Unearned Revenue | 31.37 | 28.15 | 30.61 | 3.94 | 3.99 | 4.82 | Upgrade
|
| Other Current Liabilities | 1.06 | 1.84 | 0.75 | - | - | - | Upgrade
|
| Total Current Liabilities | 68.3 | 63.64 | 91.53 | 47.52 | 30 | 24.07 | Upgrade
|
| Long-Term Debt | 14 | 23.15 | 24.93 | 24.63 | 4.98 | 4.2 | Upgrade
|
| Long-Term Leases | 2.32 | 5.2 | 8.78 | 11.7 | 10.33 | 0.95 | Upgrade
|
| Long-Term Unearned Revenue | 83.87 | 97.17 | 117.04 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | 0 | - | 0.53 | - | - | Upgrade
|
| Total Liabilities | 168.48 | 189.16 | 242.28 | 84.37 | 45.31 | 29.22 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 882.45 | 863.24 | 746.89 | 572.21 | 508.5 | 270.66 | Upgrade
|
| Retained Earnings | -881.44 | -826.36 | -654.69 | -450.48 | -280.42 | -192.37 | Upgrade
|
| Comprehensive Income & Other | 0.03 | 0.01 | -0.15 | - | - | 0.03 | Upgrade
|
| Total Common Equity | 1.05 | 36.9 | 92.06 | 121.74 | 228.09 | 78.32 | Upgrade
|
| Shareholders' Equity | 1.05 | 36.9 | 92.06 | 121.74 | 228.09 | 78.32 | Upgrade
|
| Total Liabilities & Equity | 169.53 | 226.06 | 334.34 | 206.11 | 273.4 | 107.54 | Upgrade
|
| Total Debt | 31.53 | 33.83 | 36.75 | 38.86 | 16.84 | 8.13 | Upgrade
|
| Net Cash (Debt) | 123.65 | 175.25 | 243.97 | 139.08 | 238.26 | 91.66 | Upgrade
|
| Net Cash Growth | -40.15% | -28.16% | 75.41% | -41.62% | 159.92% | 30.70% | Upgrade
|
| Net Cash Per Share | 1.02 | 1.51 | 2.60 | 1.97 | 3.87 | 2.11 | Upgrade
|
| Filing Date Shares Outstanding | 123.53 | 121.3 | 108.03 | 83.39 | 69.04 | 45.43 | Upgrade
|
| Total Common Shares Outstanding | 122.87 | 120.71 | 105.14 | 73.71 | 68.84 | 45.39 | Upgrade
|
| Working Capital | 92.26 | 150.42 | 227.69 | 141.38 | 228.58 | 77.26 | Upgrade
|
| Book Value Per Share | 0.01 | 0.31 | 0.88 | 1.65 | 3.31 | 1.73 | Upgrade
|
| Tangible Book Value | 1.05 | 36.9 | 92.06 | 121.74 | 228.09 | 78.32 | Upgrade
|
| Tangible Book Value Per Share | 0.01 | 0.31 | 0.88 | 1.65 | 3.31 | 1.73 | Upgrade
|
| Machinery | - | 10.7 | 9.78 | 7.74 | 7.48 | 7.06 | Upgrade
|
| Leasehold Improvements | - | 2.21 | 1.94 | 1.91 | 1.89 | 1.89 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.